What is Gilead Sciences, Inc. (GILD)?

Gilead Sciences, Inc. (GILD) is a stock in the Healthcare sector, Drug Manufacturers - General industry. View full analysis on Stocks360.

What is the current price of GILD?

The current price of GILD is $159.33. Prices are updated in real time on Stocks360.

What is GILD's price-to-earnings (PE) ratio?

GILD's trailing twelve-month PE ratio is -61.28, based on current price and earnings per share data available on Stocks360.

What is GILD's market capitalization?

GILD's market capitalization is $197,562,054,846.00, placing it in the large-cap tier.

Does GILD pay a dividend?

Yes. GILD has a trailing twelve-month dividend yield of 0.02%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Gilead Sciences, Inc. (GILD)

Stock analysis · NASDAQ · Healthcare · Drug Manufacturers - General

$159.33

Market Cap

$197.56B

PE (TTM)

-61.28

EPS (TTM)

N/A

Dividend Yield

2.04%

Beta

0.33

Day Range

$156.04 – $160.83

52-wk Range

$114.02 – $160.83

Avg Volume

N/A

Volume

1.90M

Gilead Sciences, Inc. (GILD) is a publicly traded company in the Healthcare sector. Latest price: $159.33. Market cap $197.56B. Trailing PE -61.28. Dividend yield 2.04%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $117.88 2026-10-28 · $159.45 (+35.26%)

Earnings

Most Recent

Aug 3, 2026

EPS $-6.75 vs est. $-7.25

Beat by $0.50

Next Earnings

Oct 29, 2026

EPS estimate $2.19

Proprietary Signals

Signal snapshot temporarily unavailable.

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-61.28×
P/S (TTM)	6.49×
P/B	16.74×
PEG	0.40×
P/FCF (TTM)	14.97×
EV / EBITDA	165.39×
EV / Sales	7.24×
Earnings Yield	-1.64%
Free Cash Flow Yield	6.68%
Dividend Yield	2.04%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$220.63B
Revenue (TTM)	$30.46B
Net Income (TTM)	-$3.23B
Free Cash Flow (TTM)	$14.85B
Net Debt	$23.07B
Working Capital	$2.92B
Gross Margin	79.59%
Operating Margin	-4.90%
Net Margin	-10.64%
Return on Equity	-16.28%
Return on Invested Capital	-3.66%